Article PDF
Avoid common mistakes on your manuscript.
References
Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479–2484.
Oei HH, van der Meer IM, Hofman A, et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570–575.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.
Folsom AR, Chambless LE, Ballantyne CM, et al.: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006, 166:1368–1373.
Lloyd-Jones DM, Liu K, Tian L, Greenland P: Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006, 145:35–42.
Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.
Rights and permissions
About this article
Cite this article
Ballantyne, C.M. Clinical Trials Report. Curr Cardio Risk Rep 1, 55–57 (2007). https://doi.org/10.1007/s12170-007-0009-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12170-007-0009-5